10-Q: Aquestive Therapeutics Reports Q1 2025 Results, Anaphylm NDA Submitted

Aquestive Therapeutics announces its Q1 2025 financial results and provides an update on its key product candidates, including the submission of the NDA for Anaphylm.

Summary

• Aquestive Therapeutics reported a net loss of $22.93 million for the three months ended March 31, 2025, compared to a net loss of $12.83 million for the same period in 2024.
• Revenues decreased by 28% to $8.72 million, primarily due to lower manufacture and supply revenue and license and royalty revenue.
• Research and development expenses decreased by 10% to $5.36 million.
• Selling, general, and administrative expenses increased by 78% to $19.07 million, driven by regulatory fees, legal fees, and commercial spending.
• The company completed the NDA submission to the FDA for Anaphylm in the first quarter of 2025.
• A pediatric study for Anaphylm showed positive topline data, consistent with previous adult studies.
• The FDA converted the approval of Libervant to a tentative approval following a court ruling, and Aquestive has ceased marketing activities in the United States.
• Aquestive is seeking FDA confirmation of Libervant's approval based on clinical superiority.
• The company had $68.66 million in cash and cash equivalents as of March 31, 2025.
• Aquestive believes its existing cash, expense management, and access to equity capital markets will fund operating needs for at least the next twelve months.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there are positive developments such as the NDA submission for Anaphylm and positive pediatric study data, the company faces significant challenges including a larger net loss, declining revenues, and legal setbacks with Libervant.

Positives

• The company successfully submitted the NDA for Anaphylm to the FDA.
• The pediatric study for Anaphylm showed positive topline data, consistent with previous adult studies.
• Aquestive believes its existing cash, expense management, and access to equity capital markets will fund operating needs for at least the next twelve months.

Negatives

• Aquestive reported a larger net loss of $22.93 million for Q1 2025 compared to $12.83 million in Q1 2024.
• Revenues decreased by 28% to $8.72 million.
• The FDA converted the approval of Libervant to a tentative approval following a court ruling, leading to a halt in marketing activities in the U.S.

Risks

• The FDA may require an advisory committee meeting prior to approval of Anaphylm.
• The company faces uncertainty regarding the FDA's decision on market access for Libervant for ARS patients aged between two and five years.
• The company is involved in ongoing legal proceedings, including product liability lawsuits and litigation with Neurelis.
• The company's future success depends on obtaining regulatory approval for its product candidates and successfully commercializing them.
• The company's ability to generate revenue is dependent on its licensees' performance and market acceptance of its licensed products.
• The company has a significant level of debt and will need to generate sufficient cash flow to meet its debt service obligations.

Future Outlook

Aquestive plans to launch Anaphylm in the first quarter of 2026, pending FDA approval, and believes its current resources will fund operations for at least the next twelve months.

Industry Context

The announcement highlights Aquestive's focus on developing alternative delivery methods for complex molecules, particularly in the treatment of severe allergic reactions and epilepsy, which aligns with the broader industry trend of seeking innovative drug delivery systems to improve patient outcomes and adherence.

Comparison to Industry Standards

• Aquestive's reliance on Suboxone revenues is similar to Indivior's historical dependence on the same product, highlighting the risks associated with single-product concentration.
• The development of Anaphylm as a sublingual epinephrine film aims to compete with existing auto-injector products like EpiPen and Auvi-Q, which have faced criticism for their device-dependent nature and usability issues.
• The legal challenges surrounding Libervant's market exclusivity are comparable to other instances where orphan drug exclusivity has been contested, such as the ongoing disputes involving products from companies like Catalyst Pharmaceuticals.
• The company's strategy of out-licensing certain products, such as Sympazan, mirrors the approach taken by other specialty pharmaceutical companies to focus on core therapeutic areas and leverage external expertise for commercialization.

Management Changes

Legal Proceedings

• Aquestive is involved in ongoing litigation with Neurelis regarding Libervant.
• The company is a defendant in product liability lawsuits related to Suboxone.
• Aquestive is named in three proposed class action lawsuits filed in Canada, along with Indivior and several other named defendants, in which the individual plaintiffs in those cases allege that their use of Suboxone products caused them dental injuries.

Stakeholder Impact

• Shareholders face increased risk due to the larger net loss and uncertainty surrounding Libervant's market access.
• Employees may experience uncertainty due to potential expense management activities and strategic shifts.
• Patients could benefit from the potential approval of Anaphylm, providing a new treatment option for severe allergic reactions.
• The company's suppliers and creditors may be affected by its financial performance and ability to meet its obligations.

Next Steps

• Aquestive will continue to communicate with the FDA on a path forward for approval of Libervant for ARS patients aged between two and five years.
• The company is preparing for a potential FDA advisory committee meeting for Anaphylm.
• Aquestive plans to initiate a product launch of Anaphylm, if approved by the FDA, in the first quarter of 2026.

Key Dates

Keywords

Aquestive Therapeutics, Anaphylm, Libervant, Financial Results, NDA Submission, Clinical Trial, FDA Approval, Revenue, Net Loss, Pharmaceuticals